KYTHERA Biopharmaceuticals Now Covered by Analysts at FBR & Co. (KYTH)
Stock analysts at FBR & Co. started coverage on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) in a report issued on Wednesday, Analyst Ratings News reports. The firm set an “outperform” rating on the stock.
A number of other analysts have also recently weighed in on KYTH. Analysts at FBR Capital Markets initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $58.00 price target on the stock. Separately, analysts at Bank of America Corp. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Friday, October 25th. They set a “buy” rating on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of KYTHERA Biopharmaceuticals from $34.00 to $45.00 in a research note to investors on Tuesday, September 17th. They now have an “overweight” rating on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $45.33.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.02% during mid-day trading on Wednesday, hitting $45.81. 31,254 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a 52 week low of $14.07 and a 52 week high of $35.80. The stock’s 50-day moving average is $27.18 and its 200-day moving average is $24.80. The company’s market cap is $973.3 million.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last released its earnings data on Tuesday, August 6th. The company reported ($0.67) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.70) by $0.03. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-2.91 earnings per share for the current fiscal year.
KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.